← All trials
NCT04839471
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2021
- Primary completion
- May 1, 2023
- Completion date
- May 1, 2023
- First posted
- Apr 9, 2021
- Last posted
- Sep 1, 2021
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of TaiwanLead sponsor
- Kaohsiung Medical UniversityCollaborator
- China Medical UniversityCollaborator
- Chang Gung UniversityCollaborator
- Taipei Veteran General hospitalCollaborator
- National Cheng Kung UniversityCollaborator
- Taiwan Cooperative Oncology GroupStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.